0.02
—
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Syntara
Its shares trade on ASX under the ticker SNT.AX. It has been listed since 10 November 2003. In the fiscal year to 30 June 2025, it reported revenue of A$7.3m and a net loss of A$7.9m. At that date it held total assets of A$21.4m and shareholders' equity of A$16.0m.
Syntara Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. The company has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Nov 2003
- Website
- pharmaxis.com.au ↗
Leadership
Pay as last reported
- Dr. Kathleen MettersNon-Executive Independent Chairman of the BoardA$112,800
- Mr. Gary PhillipsChief Executive Officer, Managing Director, Executive Director, since 2003A$830,674
- Mr. David McgarveyChief Financial OfficerA$603,032
- Dr. Jana BaskarChief Medical OfficerA$455,754
- Mr. Wolfgang JarolimekHead - Drug DiscoveryA$533,031
- Ms. Kristen MorganAlliance Management - Head of Medical and Regulatory AffairsA$360,598
- Mr. Cameron BillingsleyCompany Secretary
- Dr. Simon GreenNon-Executive DirectorA$73,627
- Mr. Waradana Hashan De SilvaNon-Executive DirectorA$32,397
- Mr. Matthew WrightInvestor Relations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 66
- Environment
- 68
- Social
- 92
- Governance
- 38
- Women in the workforce
- 48%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Syntara Ltd's lead candidate PXS-5505 targets myelofibrosis in Australia's Pharmaceuticals sector.
- The company's drug discovery engine focuses on amine oxidase inhibitors for blood-related cancers.
- Syntara's respiratory products Bronchitol and Aridol address cystic fibrosis and lung function testing.
Weaknesses
- Syntara Ltd's clinical-stage development focuses on blood-related cancers without broader market diversification.
- The company's drug candidates like PXS-4728 target niche areas such as sleep disorders and neurodegenerative diseases.
- Syntara's lead candidate PXS-5505 is specific to myelofibrosis, limiting its application scope.
Opportunities
- Syntara's pan-LOX inhibitors could expand into scar prevention and modification programs globally.
- The company's drug candidates for fibrotic diseases like kidney fibrosis and NASH present new market opportunities.
- Syntara's focus on neurodegenerative diseases with PXS-4728 may attract research partnerships.
Threats
- Syntara's reliance on a single lead candidate PXS-5505 for myelofibrosis poses development risks.
- The company's niche focus on blood-related cancers may face competition from larger pharmaceutical firms.
- Syntara's clinical-stage development requires significant funding for ongoing research and trials.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.